Search results
Results from the WOW.Com Content Network
Streptococcus canis is a group G beta-hemolytic species of Streptococcus. [1] It was first isolated in dogs, giving the bacterium its name. These bacteria are characteristically different from Streptococcus dysgalactiae, which is a human-specific group G species that has a different phenotypic chemical composition.
Domestic dogs in Belgium showed a mean prevalence of T. canis of 4.4%, those from larger kennels of up to 31%. [6] In domestic dogs in Serbia, T. canis was detectable in 30% of the animals, [7] in herding and hunting dogs in Greece in 12.8% and T. leonina in 0.7% of animals. [8]
Fecal occult blood testing (FOBT), as its name implies, aims to detect subtle blood loss in the gastrointestinal tract, anywhere from the mouth to the colon.Positive tests ("positive stool") may result from either upper gastrointestinal bleeding or lower gastrointestinal bleeding and warrant further investigation for peptic ulcers or a malignancy (such as colorectal cancer or gastric cancer).
Staphylococcus pseudintermedius is a gram-positive spherically shaped bacterium of the genus Staphylococcus [1] found worldwide. [2] It is primarily a pathogen for domestic animals, [3] [4] but has been known to affect humans as well. [5]
The stool guaiac test method may be preferable to fecal immunochemical testing (FIT) if there is a clinical concern about possible gastric or proximal upper intestinal bleeding. [37] However, although heme breakdown is less than globin during intestinal transit, false negative results can be seen with the stool guaiac tests due to degradation ...
A test kit of a CPV positive dog. Diagnosis is made through detection of CPV2 in the feces by either an ELISA or a hemagglutination test, or by electron microscopy. PCR has become available to diagnose CPV2, and can be used later in the disease when potentially less virus is being shed in the feces that may not be detectable by ELISA. [4]
For example, Shigella is a longstanding World Health Organization (WHO) target for vaccine development, and sharp declines in age-specific diarrhea/dysentery attack rates for this pathogen indicate that natural immunity does develop following exposure; thus, vaccination to prevent this disease should be feasible. The development of vaccines ...
A multi-target stool DNA test was approved in August 2014 by the FDA as a screening test for non-symptomatic, average-risk adults 50 years or older. [8] A 2017 study found this testing to be less cost effective compared to colonoscopy or fecal occult blood testing. [9]